🏆 Deal of the Week · CW 11/2024
Tubulis raised EUR 128 million in a Series B round in March 2024; the company's valuation was not disclosed. The round was upsized, reflecting strong investor conviction in Tubulis's antibody-drug conjugate pipeline targeting solid tumors. The syndicate was co-led by a broad group of specialist life sciences investors with no single lead named publicly.
Tubulis — key deal facts
| Company | Tubulis |
| Founded | 2012 |
| Headquarters | Planegg-Martinsried, Germany |
| Amount raised | EUR 128M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | Andera Partners Bayern Kapital BioMedPartners coparion Deep Track Capital EQT life science Evotec Frazier Life Sciences Fund+ High-Tech Grunderfonds Nextech Invest OCCIDENT Seventure Partners |
| Sectors | Healthcare, Biotechnology |
Who invested in Tubulis?
The Series B drew thirteen investors: Andera Partners, Bayern Kapital, BioMedPartners, coparion, Deep Track Capital, EQT Life Science, Evotec, Frazier Life Sciences, Fund+, High-Tech Gründerfonds, Nextech Invest, OCCIDENT, and Seventure Partners. The syndicate combines transatlantic institutional capital — including U.S.-based specialist funds Frazier Life Sciences and Deep Track Capital — with European life sciences specialists and German public-sector backers, reflecting cross-border confidence in the ADC sector. The involvement of Evotec, itself a drug development platform company, adds a strategic co-development dimension alongside the financial investors.
What does Tubulis do?
Tubulis is a clinical-stage biotechnology company developing next-generation antibody-drug conjugates for solid and hematologic tumors. Its proprietary platforms — P5 conjugation, Tubutecan, and Alco5 — are designed to produce ultra-stable ADCs with high drug-to-antibody ratios and reduced off-target toxicity. Lead programs include TUB-040, targeting NaPi2b in ovarian and lung cancer, and TUB-030, targeting 5T4 across solid tumor indications. The company was founded in 2018 by CEO Dr. Dominik Schumacher and CSO Dr. Jonas Helma-Smets, and is headquartered in Planegg-Martinsried, near Munich, Germany.
Tubulis valuation & multiples
Explore the benchmarks: Series B.
Frequently asked questions
How much did Tubulis raise in its Series B?
Tubulis raised EUR 128 million in an upsized Series B round that closed in March 2024.
What is Tubulis's valuation?
Tubulis's valuation was not disclosed in connection with the Series B financing.
Who invested in Tubulis?
The Series B was backed by Andera Partners, Bayern Kapital, BioMedPartners, coparion, Deep Track Capital, EQT Life Science, Evotec, Frazier Life Sciences, Fund+, High-Tech Gründerfonds, Nextech Invest, OCCIDENT, and Seventure Partners.
When was Tubulis founded and where is it based?
Tubulis was founded in 2018 and is headquartered in Planegg-Martinsried, near Munich, Germany.
Source: original announcement — read the full report.